Loss cell powerhouses linked
Andhra Pradesh ~ India ~ International ~ City ~ Entertainment ~ Business ~ Sports ~ Technology ~ Health ~ Features
Twitter ~ Facebook
Home / Technology News / 2010 / October 2010 / October 8, 2010
Loss of cell powerhouses linked to Parkinson's
RSS / Print / Comments

Columbia University

How stem cells shape up to their surroundings

Loss of cell powerhouses linked to Parkinson's

Loss of cell powerhouses linked to Parkinson's

More on Columbia University

Protein

Reportlinker Adds Global Milk Industry

Cellular defect that leads to cancer discovered

Why family history ups Alzheimers risk - especially from the maternal side

More on Protein

Diabetes

Study to find whether leptin helps type 1 diabetic patients

Blame your mom for your muffin top or thunder thighs

Clinical trials show effective weight loss strategies for obese

More on Diabetes

Harvard Medical School

Loss of cell powerhouses linked to Parkinson's

Loss of cell powerhouses linked to Parkinson's

Stress of heavy combat can be life-long: Study

More on Harvard Medical School

Heart attack

F1 legend James Hunt 'slept with 5,000 women'

A cuppa thrice a day can 'protect against heart attacks'

Loss of cell powerhouses linked to Parkinson's

More on Heart attack

Technology News

Study to find whether leptin helps type 1 diabetic patients
To determine whether adding the hormone leptin to standard insulin therapy might help rein in the tumultuous blood-sugar levels of people with type 1 (insulin-dependent) diabetes, a clinical trial at UT Southwestern Medical Center is being carried out. ANI

Why deaf have 'super vision'
Researchers have found reasons for the enhanced abilities in the remaining senses of deaf people. ANI

Tsunami risk higher than expected in LA, other major cities
A new study has revealed that the risk of destructive tsunamis is in places such as Kingston, Istanbul, and Los Angeles. ANI

Loss of cell powerhouses linked to Parkinson's

Scientists have bolstered the link between Parkinsons disease and the loss of cellular powerhouses called mitochondria after conducting a painstaking analysis of more than 400 brain tissue samples.


London, Oct 8 : Scientists have bolstered the link between Parkinson's disease and the loss of cellular powerhouses called mitochondria after conducting a painstaking analysis of more than 400 brain tissue samples.

If supported by additional studies, the results could warrant clinical trials of existing drugs (currently used to treat other diseases) that activate a key pathway able to repair and replace broken mitochondria, reports Nature.

In recent years, evidence has been mounting that damaged mitochondria contribute to the neurological damage wrought by the disease.

For the latest study, neurologist Clemens Scherzer of Harvard Medical School in Boston, Ma*sachusetts - lead author on the current study - and an international consortium of researchers began by profiling patterns of gene expression in diseased versus healthy brains.

The team gathered data from roughly ten times more samples than had ever before been analysed in a single Parkinson's disease study, says Scherzer, allowing his team to conduct a more sensitive sweep of gene expression changes.

The trawl through millions of data points yielded ten gene sets not previously a*sociated with Parkinson's disease. All are involved in mitochondrial function and energy generation.

What's more, genes regulated by a single protein called PGC-1a were expressed at abnormally low levels in patients with Parkinson's disease. Increasing the expression of that protein in rat neurons grown in culture was enough to reduce the toxic effects of MPTP and rotenone.

That, says Scherzer, suggests that PGC-1a-activating drugs might stave off the damage to the brain caused by Parkinson's disease.

Such drugs have already been widely pursued as potential therapies for type 2 diabetes, and some have already been approved for that use. Avandia (rosiglitazone), a diabetes drug recently pulled from the European market because it raises the risk of heart attack, activates a key protein in the PGC-1a pathway.

But a related drug called Actos (pioglitazone) has not been firmly linked to heart attack and remains in use. Beal says that a clinical trial to test Actos in patients with Parkinson's disease has already been approved by regulators.

The gene expression analysis will be a valuable tool for future research, says Asa Abeliovich, a neurologist at Columbia University Medical Center in New York.

However, it is still unclear whether the PCG-1a pathway is specifically suppressed in Parkinson's disease, or if that suppression is just a consequence of the widespread mitochondrial damage that is provoked when neurons become damaged, he adds.

The study has been published in Science Translational Medicine1.

ANI

Link to this page

Suggested pages for your additional reading
AndhraNews.net on Facebook






© 2000-2017 AndhraNews.net. All Rights Reserved and are of their respective owners.
Disclaimer, Terms of Service & Privacy Policy | Contact Us